What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?

• Published in: Cell death and differentiation Vol. 29; no. 6; pp. 1079 - 1093
• Main Authors: Brinkmann, Kerstin, Ng, Ashley P, de Graaf, Carolyn A, Strasser, Andreas
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.06.2022; Nature Publishing Group UK
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antitumor agents; Apoptosis; Apoptosis Regulatory Proteins - metabolism; BAX protein; Bcl-2 protein; Bcl-x protein; bcl-X Protein - metabolism; Cancer therapies; Cell death; Cell Line, Tumor; Cytokines; DNA damage; Drug delivery; Drug development; Drugs; Embryogenesis; Humans; Major outer membrane protein; Mcl-1 protein; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein - metabolism; Neoplasms - drug therapy; Neoplasms - genetics; Post-transcription; Protein structure; Proteins; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Review; Transformed cells; Tumorigenesis
• ISSN: 1350-9047; 1476-5403
• DOI: 10.1038/s41418-022-00987-0

In many human cancers the control of apoptosis is dysregulated, for instance as a result of the overexpression of pro-survival BCL-2 proteins. This promotes tumorigenesis by protecting nascent neoplastic cells from stress and renders malignant cells resistant to anti-cancer agents. Therefore, several BH3 mimetic drugs targeting distinct pro-survival proteins have been developed. The BCL-2 inhibitor Venetoclax/ABT-199, has been approved for treatment of certain blood cancers and tens of thousands of patients have already been treated effectively with this drug. To advance the clinical development of MCL-1 and BCL-XL inhibitors, a more detailed understanding of their distinct and overlapping roles in the survival of malignant as well as non-transformed cells in healthy tissues is required. Here, we discuss similarities and differences in pro-survival BCL-2 protein structure, subcellular localisation and binding affinities to the pro-apoptotic BCL-2 family members. We summarise the findings from gene-targeting studies in mice to discuss the specific roles of distinct pro-survival BCL-2 family members during embryogenesis and the survival of non-transformed cells in healthy tissues in adults. Finally, we elaborate how these findings align with or differ from the observations from the clinical development and use of BH3 mimetic drugs targeting different pro-survival BCL-2 proteins.